Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CASP3 | P42574 | 1/20 | 0.49 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.44 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30562288 | 0.89 | GAA (0.61) | GAAALDH1A1MAPTCYP1A2KMT2A | |
| SCHEMBL8973558 | 0.88 | GAA (0.59) | GAAALDH1A1MAPTCYP1A2KMT2A | |
| SCHEMBL30645031 | 0.88 | GAA (0.59) | GAAALDH1A1MAPTCYP1A2KMT2A | |
| SCHEMBL6179513 | 0.86 | GAA (0.57) | GAAALDH1A1MAPTCYP1A2KMT2A | |
| SCHEMBL16938605 | 0.86 | TDP1 (0.59) | GAAALDH1A1MAPTCYP1A2KMT2A | |
| Hydrochloric Acid SCHEMBL5640958 | 0.85 | GAA (0.56) | GAAALDH1A1MAPTCYP1A2KMT2A | |
| SCHEMBL22326350 | 0.84 | GAA (0.88) | GAAALDH1A1MAPTCYP1A2KMT2A | |
| SCHEMBL17384166 | 0.82 | GAA (0.53) | GAAALDH1A1MAPTCYP1A2KMT2A | |
| SCHEMBL6524461 | 0.81 | KMT2A (0.74) | GAAALDH1A1MAPTCYP1A2KMT2A | |
| SCHEMBL29367470 | 0.81 | KMT2A (0.74) | GAAALDH1A1MAPTCYP1A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059784-B2 | Oxime ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-11059784-B2 | Oxime ether compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210147361-A1 | OXIME ETHER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210147361-A1 | OXIME ETHER COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-05-20 | — | — | US | disclosed |
| WO-2019032631-A1 | OXIME ETHER COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-02-14 | — | — | WO | disclosed |
| US-20100226875-A1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM DYNAMIC MIXTURES | FIRMENICH SA (CH) | 2010-09-09 | — | — | US | disclosed |
| EP-2010293-A2 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM DYNAMIC MIXTURES | Firmenich S.A. (CH) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007085991-A2 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM DYNAMIC MIXTURES | FIRMENICH SA (CH) | 2007-08-02 | — | — | WO | disclosed |
| WO-1997033590-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| WO-1997033591-A1 | A METHOD OF TREATING DISORDERS RELATED TO CYTOKINES IN MAMMALS | NOVO NORDISK A/S (DK) | 1997-09-18 | — | — | WO | disclosed |
| US-5430027-A | 2-chloro-N6 -substituted adenosines, their pharmaceutical compositions, and activity in treating ischemias | NOVO NORDISK A/S (DK) | 1995-07-04 | — | — | US | disclosed |
| EP-0607367-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1994-07-27 | — | — | EP | disclosed |
| WO-1993023417-A1 | NOVEL ADENOSINE DERIVATIVES | NOVO NORDISK A/S (DK) | 1993-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100226875-A1 | CONTROLLED RELEASE OF ACTIVE COMPOUNDS FROM DYNAMIC MIXTURES | HPD, TRHDE, BPHL | GAA 3816/4885ALDH1A1 953/4885MAPT 2502/4885 |
| US-20210147361-A1 | OXIME ETHER COMPOUNDS | S1PR1, S1PR3, S1PR2 | GAA 4798/4885ALDH1A1 1798/4885MAPT 4567/4885 |
| US-11059784-B2 | Oxime ether compounds | S1PR1, S1PR3, S1PR2 | GAA 4805/4885ALDH1A1 2003/4885MAPT 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.